Abstract:Microbes, toxins, therapeutics, and cells are often instilled into lungs of mice to model diseases and test experimental interventions. Consistent pulmonary delivery is critical for experimental power and reproducibility, but we observed variation in outcomes between handlers using different anesthetic approaches for intranasal dosing in mice. We therefore used a radiotracer to quantify lung delivery after intranasal dosing under inhalational (isoflurane) versus injectable (ketamine/xylazine) anesthesia in C57BL/6 mice. We found that ketamine/xylazine anesthesia resulted in delivery of a greater proportion (52 ± 9%) of an intranasal dose to lungs relative to isoflurane anesthesia (30 ± 15%). This difference in pulmonary dose delivery altered key outcomes in models of viral and bacterial pneumonia, with mice anesthetized with ketamine/xylazine for intranasal infection with influenza A virus or Pseudomonas aeruginosa developing more robust lung inflammation responses relative to control animals randomized to isoflurane anesthesia. Pulmonary dosing efficiency through oropharyngeal aspiration was not affected by anesthetic method and resulted in delivery of 63 ± 8% of dose to lungs, and a nonsurgical intratracheal dosing approach further increased lung delivery to 92 ± 6% of dose. The use of either of these more precise dosing methods yielded greater experimental power in the bacterial pneumonia model relative to intranasal infection. Both anesthetic approach and dosing route can impact pulmonary dosing efficiency. These factors affect experimental power and so should be considered when planning and reporting studies involving delivery of fluids to lungs of mice.NEW & NOTEWORTHY Many lung research studies involve dosing fluids into lungs of mice. In this study, the authors measure lung deposition using intranasal (i.n.), oropharyngeal aspiration (o.a.), and intratracheal (i.t.) dosing methods in mice. Anesthetic approach and administration route were found to affect pulmonary dosing efficiency. The authors demonstrate that refinements to dosing techniques can enable reductions in the number of animals needed for bacterial and viral pneumonia studies.

Design Considerations for Intratracheal Delivery Devices to Achieve Proof-of-Concept Dry Powder Biopharmaceutical Delivery in Mice

Dry powder inhaler design and particle technology in enhancing Pulmonary drug deposition: challenges and future strategies

Dry Powder Aerosol Delivery Systems: Current and Future Research Directions

Designing Aerosol Therapies Based on the Integrated Evaluation of In Vitro, In Vivo, and In Silico Data

Optimizing anesthesia and delivery approaches for dosing into lungs of mice

Development of a dry powder insufflation device with application in in vitro cell-based assays in the context of respiratory delivery

Design, development, and technical considerations for dry powder inhaler devices

Combining experimental and computational techniques to understand and improve dry powder inhalers

In-vitro and Particle Image Velocimetry Studies of Dry Powder Inhalers

Identification of Stability Constraints in the Particle Engineering of an Inhaled Monoclonal Antibody Dried Powder

Inhalable Dry Powders for Lung mRNA Delivery

Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model

Cfd Simulation and Characterization of A Device for Powdered Pharmaceuticals and Biologicals Delivery

Numerical study of effects of device design on drug delivery efficiency for an active dry powder inhaler

Understanding the role of swirling flow in dry powder inhalers implications for design considerations and pulmonary delivery

Inhalation powder development without carrier: How to engineer ultra-flying microparticles?

Formulation strategies, preparation methods, and devices for pulmonary delivery of biologics

Dosing challenges in respiratory therapies

Method for Pulmonary Administration Using Negative Pressure Generated by Inspiration in Mice

An In Silico Investigation of a Lobe-Specific Targeted Pulmonary Drug Delivery Method

Recent developments in the computational simulation of dry powder inhalers